Restart Life Sciences Corp

Flagship Developments

Autism Spectrum

Restart Life Sciences is at the forefront of developing natural remedies specifically tailored for individuals on the autism spectrum. Our focus is on creating innovative health foods that address the unique needs of this community. Recognizing the significant gap in the marketplace for effective, natural solutions, we are committed to creating high-quality products that promote overall wellness and support healthier lifestyles.

Health-Related Foods

Restart Life Sciences is dedicated to developing health-related foods that promote both mind and body wellness for healthy living. Our mission is to create innovative, nutrient-rich products that support mental clarity, physical vitality, and overall well-being. By focusing on holistic nutrition, we aim to empower individuals to lead healthier, more balanced lives. Join us as we explore the intersection of nutrition and wellness, paving the way for a brighter future.

Canada’s First Psilocybin Clinical Trial for Fragile X Syndrome

We are partnered with KGK Science to conduct the Phase IIA clinical trial which is being carried out at the KGK facility in London, Ontario, Canada. This 10-person, open-label study will assess repetitive, oral low-dose psilocybin therapy for FXS. The Company intends to confirm changes in behavioural symptoms with state-of-the-art diagnostic and therapeutic mRNA and serotonin biomarker technology, combined with machine learning artificial intelligence (AI).

Orphan Drug Designation (FDA and EMA)

The company received orphan drug designation from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for its propriety psilocybin drug for the treatment of fragile X syndrome (FXS), the leading genetic cause of symptoms related to autism spectrum disorder (ASD).

Medicines that have been granted an orphan designation from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) receive benefits, including but not limited to:

Seven-Ten years of market exclusivity: FDA and EMA cannot approve the same drug for the same indication.
25% federal tax credit for expenses incurred in conducting clinical research within the United States.
Waiver of Prescription Drug User Fee Act (PDUFA) fees: a value of approximately $2.9 million.
Ability to qualify to compete for research grants from the Office of Orphan Products Development (OOPD) to support clinical studies.
Eligibility to receive regulatory assistance and guidance from the FDA in the design of an overall drug development plan.

IP Conveyance Agreement with Ludwig Enterprises Inc. (LUDG)

Under the terms of the agreement, in consideration of the assignment of the property (Intellectual property and patent of the mRNA neuro panel and serotonin assay, along with any and all data accumulated testing these assays), Ludwig issue to the company 750,000 restricted shares of its common stock. In addition, for a period of 10 years from the date of the agreement, Ludwig shall pay the company a 2.5-per-cent royalty on all revenue derived from the commercialization of the property up to the amount of $245,712 (U.S.) and 5 per cent on any revenue over this amount.

Executive Team

Steve Loutskou

President, CEO

With over 20 years of experience as a seasoned serial entrepreneur, Mr. Loutskou has built a remarkable career filled with numerous success stories. He excels in guiding early-stage startups through to mature commercialization, showcasing exceptional skills in navigating the complexities of financing. His extensive background in business management, operations, and financing spans various industry sectors.

Mr. Loutskou originally co-founded Plant & Co, which has since evolved into Happy Belly Food Group (CSE: HBFG). Happy Belly is a prominent consolidator of emerging food brands, with over 400 restaurants in the pipeline.

As a trailblazer in innovative ventures, Mr. Loutskou's strategic vision and financial expertise have propelled startups to success while attracting investment. His ongoing influence is crucial in shaping the future of business through insightful strategies and proficient management.

Rebecca Hudson, CPA, CA

CFO

Ms. Hudson is a Chartered Professional Accountant (CPA, CA) with over 23 years of experience in accounting and financial reporting, corporate finance, risk management, financial audit and corporate governance, serving a range of industries, including mining and exploration, oil and gas, cannabis, manufacturing and retail, and not-for-profit.

Ms. Hudson has served as CFO, and consulted for, a number of publicly-listed resource companies with projects in North and South America and across Europe. Ms. Hudson holds a Bachelor’s Degree and a Masters of Accounting from the University of Waterloo.

She is a strategic, senior financial leader with a proven record in building financial operations and developing talent in growth-focused organizations.

Dr. Georg Hochwimmer

Director

Dr. Hochwimmer is chief analyst at General Research GmbH, a leading Munich-based securities research and analysis firm. Dr. Hochwimmer is a noted business consultant and academic responsible for aiding in the development of several highly profitable companies throughout Europe.

He serves as the chief executive officer of supraMAT Technologies AG, which is a business incubator for German technology companies. He founded leading German technical start-ups, such as NGP Polymers, SmartDyelivery and Trophosys. He is also a managing director of Microdrop Technologies, which is a globally leading 3-D microprinting company.

Dr. Hochwimmer has earned advanced degrees in chemistry and mechanical engineering.

Derek Ivany

Director

Derek Ivany has more than two decades of experience successfully working with publicly traded companies and helping generate significant shareholder value in a variety of sectors through corporate development outreach, mergers and acquisitions, capital markets support and other strategic value enhancement initiatives.

Having worked with a variety of international groups, Mr. Ivany has established a network of high-profile business leaders across such sectors as medicinal products, health and wellness, mining, oil and gas, coffee, technology, horse racing and real estate.

Kelly Pladson

Corporate Administrator

Kelly Pladson has provided corporate governance and regulatory compliance services to many TSX Venture and CSE listed companies since 2009.

She works closely with the company’s CEO and legal counsel in maintaining corporate records, managing the day to day operations of the company and ensuring the company’s filings with the securities commissions and exchanges are accurately filed and in accordance with their deadlines. Prior to 2009, Ms. Pladson was an investment advisor’s assistant for two years.

About Us